They clearly indicated superior efficacy in the PAOD‐group, only (see Table 1 ), suggesting that overall superiority was achieved mainly by the fact that a weighted average has been calculated (loosely speaking) from a strongly positive treatment effect in PAOD (risk difference –1.9% in favor of clopidogrel), a weak trend in patients with previous stroke (risk difference –1.0% in favor of clopidogrel) and a borderline neutral effect in patients with previous myocardial infarction (risk difference 0.3% in favor of aspirin).
← all excerpts
Does it help that efficacy has been proven once we start discussing (added) benefit?
1
—
—